Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Scientists develop first polymeric material that is sensitive to very low levels of NIR irradiation

Scientists at the University of California, San Diego have developed what they believe to be the first polymeric material that is sensitive to biologically benign levels of near infrared (NIR) irradiation, enabling the material to disassemble in a highly controlled fashion.

4 Oct 2011

TriLogic, Mission Pharmacal partner to develop new drug delivery system

Mission Pharmacal Company announced today that it is developing a new drug delivery system utilizing technology developed by TriLogic Pharma. The delivery system will be based upon TriLogic's proprietary drug delivery platform TRI-726 and will be licensed to Mission Pharmacal for future drug development.

4 Oct 2011

Halozyme commences HTI-501 clinical trial for cellulite in women

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of a Phase 1/2 clinical trial with HTI-501 (rHuCAT-L) in women with moderate to severe edematous fibrosclerotic panniculopathy (also known as cellulite).

28 Sep 2011

University of Utah organic chemist wins National Medal of Science

University of Utah organic chemist Peter J. Stang has won a National Medal of Science - the highest U.S. honor for a scientist or engineer - and is tentatively scheduled to be honored by President Barack Obama at the White House later this year.

28 Sep 2011

Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.

27 Sep 2011

Pacira announces data from EXPAREL clinical study presented at ASPS 2011 meeting

Pacira Pharmaceuticals, Inc. today announced that the company's lead investigational product for postsurgical pain management, EXPAREL, was highlighted in the "Hot Topics in Plastic Surgery" panel at the annual scientific assembly of the American Society of Plastic Surgeons (ASPS) in Denver, Colo.

26 Sep 2011

Gold nanowires in engineered cardiac patches could help heart attack patients

A team of physicians, engineers and materials scientists at Children's Hospital Boston and the Massachusetts Institute of Technology have used nanotechnology and tiny gold wires to engineer cardiac patches, with cells all beating in time, that could someday help heart attack patients.

26 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

Liposomes block HIV infection in early tests

Could engineered fatty particles help prevent AIDS? Liposomes block HIV infection in early tests; could be a cost-effective preventive for developing countries

20 Sep 2011

Preclinical studies shows EmPAC more effective than Taxol

Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone’s proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi’s sarcoma.

19 Sep 2011

Meda, Moberg Derma enter license agreement for Nalox to treat onychomycosis

Moberg Derma AB and Meda AB have entered into a license agreement covering rights for Nalox - Moberg Derma's patented product for the treatment of discolored and damaged nails caused by nail fungus or nail psoriasis.

19 Sep 2011

Generex issues update on Antigen Express spinout

Generex Biotechnology Corporation today provided an update on the status of the previously announced spinout of its wholly-owned subsidiary, Antigen Express, Inc..

16 Sep 2011

Study examines effects of carbon nanoparticles on living cells

A study by researchers from the schools of science and medicine at Indiana University-Purdue University Indianapolis examines the effects of carbon nanoparticles (CNPs) on living cells. This work is among the first to study concentrations of these tiny particles that are low enough to mimic the actual exposure of an ordinary individual.

16 Sep 2011

USPTO issues Certificate of Registration for Echo's SYMPHONY and PRELUDE trademarks

Echo Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude SkinPrep System for transdermal drug delivery, today announced that the company has received Certificates of Registration from the United States Patent and Trademark Office for its SYMPHONY and PRELUDE trademarks, as used with Echo's tCGM system and mechanical skin ablator, respectively.

15 Sep 2011

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.

14 Sep 2011

Impax confirms JALYN patent challenge

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed in connection with JALYN capsules.

13 Sep 2011

Valeritas completes Series C round of financing

Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, announced today it has completed a significant Series C round of financing of $150 million.

12 Sep 2011

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company's patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy.

12 Sep 2011

Recruitment complete in Moberg Derma's MOB-015 phase II study for nail fungus

Moberg Derma AB has successfully completed the recruitment of 237 patients with nail fungus (onychomycosis) to participate in the ongoing MOB-015 phase II study.

12 Sep 2011

Aura's NanoSmart platform can enable earlier detection, treatment of cancers

Aura Biosciences, Inc., a biotech company focused on the development of nano-enabled drug delivery systems, has completed several pre-clinical research programs. The resulting data suggest that Aura's NanoSmart platform can enable earlier detection of cancers and distant metastases; and then provide precisely targeted treatment of those cancers.

9 Sep 2011